2023年11月2日 · DSP-5336 is an investigational, oral small molecule designed to inhibit the menin and MLL protein interaction. Methods: A Phase 1/2 study of DSP-5336 is being …

2023年12月11日 · DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological …

2024年6月14日 · DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, …

2024年7月15日 · DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in gene expression and …

2024年7月15日 · The FDA has granted DSP-5336 a fast track designation, supported by updated findings from an ongoing phase 1/2 study (NCT04988555). DSP-5336 is an investigational …

2024年7月16日 · The FDA has granted fast track designation to the investigational small molecule menin inhibitor DSP-5336 as a treatment for patients with relapsed/refractory acute myeloid …

2022年8月3日 · DSP-5336 is an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein.

2021年11月23日 · Results: We generated DSP-5336, a novel, potent, and orally bioavailable MENIN-MLL interaction inhibitor for the treatment of acute leukemia patients with MLL -r or …

DSP-5336, a novel, investigational oral small-molecule agent, was developed to disrupt binding between menin and mixed-lineage leukemia (MLL/KMT2A) proteins. Nonclinical studies of …

2022年8月3日 · Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) granted …